PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 01 2021
Historique:
received: 04 11 2020
accepted: 04 01 2021
entrez: 22 1 2021
pubmed: 23 1 2021
medline: 28 9 2021
Statut: epublish

Résumé

Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (-) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3.

Identifiants

pubmed: 33479394
doi: 10.1038/s41598-021-81667-w
pii: 10.1038/s41598-021-81667-w
pmc: PMC7820576
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
IFNG protein, human 0
IRF3 protein, human 0
Interferon Regulatory Factor-3 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1982

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 18K08652
Organisme : Japan Society for the Promotion of Science
ID : 18K08652
Organisme : Japan Society for the Promotion of Science
ID : 19K09099

Références

Wiley Interdiscip Rev Syst Biol Med. 2020 Nov;12(6):e1489
pubmed: 32307915
Carcinogenesis. 2020 Nov 16;:
pubmed: 33196828
Gastric Cancer. 2020 Jul;23(4):565-578
pubmed: 32468420
Cancer Lett. 2014 Apr 28;346(1):122-8
pubmed: 24368188
Carcinogenesis. 2017 Oct 26;38(11):1084-1091
pubmed: 28968686
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Res. 2012 Jul 15;72(14):3445-50
pubmed: 22761333
Clin Cancer Res. 2017 Mar 1;23(5):1220-1226
pubmed: 27620277
Cell Immunol. 2016 Dec;310:141-149
pubmed: 27641636
Cancer Sci. 2018 Jan;109(1):43-53
pubmed: 29034543
Microbes Infect. 2015 Jun;17(6):426-39
pubmed: 25777301
Sci Rep. 2017 Dec 19;7(1):17810
pubmed: 29259270
PLoS One. 2017 Apr 20;12(4):e0176045
pubmed: 28426752
Leukemia. 2019 Jan;33(1):132-147
pubmed: 29946193
Sci Rep. 2019 May 1;9(1):6769
pubmed: 31043675
Gastric Cancer. 2021 Jan;24(1):60-71
pubmed: 32506298
Gastroenterology. 2015 Jan;148(1):137-147.e9
pubmed: 25254613
Cancer Res. 2011 Dec 1;71(23):7187-97
pubmed: 21990320
Int J Oncol. 2015 Apr;46(4):1421-34
pubmed: 25633561
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Cancer Res. 2019 Jun 1;79(11):2909-2922
pubmed: 30737234
Gastric Cancer. 2020 Nov;23(6):961-973
pubmed: 32367440
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Gastric Cancer. 2020 May;23(3):510-519
pubmed: 31863227
J Exp Med. 2009 Sep 28;206(10):2091-9
pubmed: 19720839
Genes Chromosomes Cancer. 2016 Aug;55(8):626-39
pubmed: 27106868
BMC Med Genomics. 2017 Dec 06;10(1):74
pubmed: 29212506
Microorganisms. 2019 Jun 24;7(6):
pubmed: 31238570
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
pubmed: 23674495
Int Immunopharmacol. 2017 Sep;50:121-129
pubmed: 28651122
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052

Auteurs

Hiroshi Nakano (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Motonobu Saito (M)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. moto@fmu.ac.jp.

Shotaro Nakajima (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Department of Medical Electrophysiology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.

Katsuharu Saito (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Yuko Nakayama (Y)

First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, 409-3898, Japan.

Koji Kase (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Leo Yamada (L)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Yasuyuki Kanke (Y)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Hiroyuki Hanayama (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Hisashi Onozawa (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Hirokazu Okayama (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Shotaro Fujita (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Wataru Sakamoto (W)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Zenichiro Saze (Z)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Tomoyuki Momma (T)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Kosaku Mimura (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.

Shinji Ohki (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Akiteru Goto (A)

Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, 010-8543, Japan.

Koji Kono (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH